However, the use of administered GM-CSF to treat non-COVID ARDS has had mixed success, where it was shown to improve the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FIO2) (85), but it did not increase the number of ventilator-free days in patients with ARDS (86). Here, CSF2 is linked to acute respiratory distress syndrome.